AVRO - AVROバイオ （AVROBIO Inc.） AVROバイオAVROのチャート
AVROの企業情報
| symbol | AVRO |
|---|---|
| 会社名 | AVROBIO Inc （AVROバイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 AVROBIO Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01 AVR-RD-02 AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis. AVROバイオは米国のバイオ医薬品企業。臨床段階で、主に希少疾患に対する遺伝子治療に焦点を当てた医薬品の開発・商業化に従事する。同社はリソソ―ム蓄積症に対する幹細胞遺伝子治療を開発し、一度の投与で効果を表す医薬品を手がける。パイプラインにはゴ―シェ病、ポンペ病、シスキシン症の治療薬を含む。本社所在地はマサチュ―セッツ州ケンブリッジ。 AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario. |
| 本社所在地 | One Kendall Square Building 300 Suite 201 Cambridge MA 02139 USA |
| 代表者氏名 | Bruce Booth ブルースブース |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 781-962-6030 |
| 設立年月日 | 42309 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 34人 |
| url | www.avrobio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/avro |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.03900 |
| 終値（lastsale） | 25.6 |
| 時価総額（marketcap） | 612783052.8 |
| 時価総額 | 時価総額（百万ドル） 578.31400 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 423.29900 |
| 当期純利益 | 当期純利益（百万ドル） -35.06700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Avrobio Inc revenues was not reported. Net loss applicable to common stockholders increased from $4.7M to $21M. Higher net loss reflects Research and developme increase from $3.3M to $12.9M (expense) General and administrative increase from $1.2M to $3.9M (expense) Gains/Losses on Trading Derivatives increase from $35K to $1.6M (expense). |
AVROのテクニカル分析
AVROのニュース
AVROBIO GAAP EPS of -$0.57 misses by $0.12 2023/03/23 11:56:54 Seeking Alpha
AVROBIO press release (AVRO): Q4 GAAP EPS of -$0.57 misses by $0.12.As of Dec
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update 2023/03/23 11:00:00 Business Wire
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported
AVROBIO (AVRO) Investor Presentation - Slideshow 2023/03/10 13:42:50 Seeking Alpha
The following slide deck was published by AVROBIO, Inc.
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference 2023/03/03 12:00:00 Wallstreet:Online
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled “Orphan Neuro Corporate Panel” at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 AM ET at the Boston Marriott Copley Place
What Can AVROBIO Inc. (NASDAQ: AVRO) Expect In 2023? 2023/02/24 13:00:00 Stocks Register
AVROBIO Inc. (NASDAQ:AVRO) price on Thursday, February 23, fall -18.63% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.31. A look at the stock’s price movement, the close in the last trading session was $1.61, moving within a range at $1.29 and $1.60. The beta value (5-Year … What Can AVROBIO Inc. (NASDAQ: AVRO) Expect In 2023? Read More »
AVROBIO GAAP EPS of -$0.57 misses by $0.12 2023/03/23 11:56:54 Seeking Alpha
AVROBIO press release (AVRO): Q4 GAAP EPS of -$0.57 misses by $0.12.As of Dec
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update 2023/03/23 11:00:00 Business Wire
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported
AVROBIO (AVRO) Investor Presentation - Slideshow 2023/03/10 13:42:50 Seeking Alpha
The following slide deck was published by AVROBIO, Inc.
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference 2023/03/03 12:00:00 Wallstreet:Online
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled “Orphan Neuro Corporate Panel” at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 AM ET at the Boston Marriott Copley Place
What Can AVROBIO Inc. (NASDAQ: AVRO) Expect In 2023? 2023/02/24 13:00:00 Stocks Register
AVROBIO Inc. (NASDAQ:AVRO) price on Thursday, February 23, fall -18.63% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.31. A look at the stock’s price movement, the close in the last trading session was $1.61, moving within a range at $1.29 and $1.60. The beta value (5-Year … What Can AVROBIO Inc. (NASDAQ: AVRO) Expect In 2023? Read More »
AVROBIO Inc. (AVRO) did well last session? 2022/09/28 12:32:00 US Post News
A share of AVROBIO Inc. (NASDAQ:AVRO) closed at $0.65 per share on Tuesday, down from $0.73 day before. While AVROBIO Inc. has underperformed by -10.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVRO fell by -89.04%, with highs and lows ranging from $6.62 to $0.66, […]
AVROBIO, Inc.: AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress 2022/09/27 11:03:00 Finanz Nachrichten
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on …
AVROBIO Inc. (AVRO) can excel with these strategies 2022/09/21 15:32:00 US Post News
A share of AVROBIO Inc. (NASDAQ:AVRO) closed at $0.77 per share on Tuesday, down from $0.80 day before. While AVROBIO Inc. has underperformed by -3.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVRO fell by -87.57%, with highs and lows ranging from $6.62 to $0.74, […]